Relationship between body surface area and ALT normalization after long-term lamivudine treatment

Table 1 Baseline characteristics of patients treated for 1 year¹

	Total (range)	SR-ALT	NR-ALT	SR-DNA	NR-DNA
n	249	150	99	183	66
Male/female	180/67	99/51	82/17	127/54	53/13
ALT (U/L)	211.1±402.4 (16-4491)	242.1±424.2	163.6±363.6	240.3±462.2	128.8±88.1
Albumin (g/dL)	3.8±0.6 (2.2-4.9)	3.8±0.6	3.8±0.6	3.8±0.6	3.9±0.6
Bilirubin (mg/dL)	1.3±1.7 (0.1-12.9)	1.4±1.8	1.2±1.5	1.4±1.9	1.0±1.1
Platelet (104/mL)	14.1±6.1 (2.6-35.5)	14.2±5.8	14.0±6.5	13.9±6.2	14.9±5.6
BSA (m2)	1.70±0.20 (1.25-2.17)	1.66±0.17	1.75±0.18	1.69±0.18	1.73±0.18
HBV-DNA
≤5 (LEG/mL)	31	20	11	29	2
5< ≤6	33	18	15	27	6
6< ≤7	68	41	27	52	16
7<	117	71	46	75	42
HBeAg +/–	135/110	83/64	52/46	84/96	51/14
Age (yr)	48.6±11.6 (19-73)
CH/LC [Child A/B/C]	162/87 [61/11/15]

¹Data are shown as mean±SD.

Table 2 Univariate analysis of the effects of lamivudine treatment for 1 year

Variables	χ2	P
Biological effects
ALT (U/L)	2.963405	0.0852
Albumin (g/dL)	0.230408	0.6312
Bilirubin (mg/dL)	0.934082	0.3338
Platelet count (104/mL)	0.097459	0.7549
BSA (m2)	15.96269	<0.0001
HNV-DNA (LEG/mL)	0.000983	0.975
HbeAg	0.275	0.6
Virological effects
ALT (U/L)	8.293809	0.004
Albumin (g/dL)	3.353949	0.067
Bilirubin (mg/dL)	3.258437	0.0711
Platelet count (104/mL)	1.33191	0.2485
BSA (m2)	2.58664	0.1078
HNV-DNA (LEG/mL)	14.3801	0.0001
HbeAg	19.514	<0.0001

Table 3 Multivariate analysis on the effects of lamivudine treatment for 1 year

Variable	χ2	P
Biological effects
ALT (U/L)	1.921529	0.1657
BSA (m2)	15.96269	0.0002
Virological effects
ALT (U/L)	9.797455	0.0017
Albumin (g/dL)	5.106762	0.0238
Bilirubin (mg/dL)	0.450406	0.5021
Platelet count (104/mL)	0.009626	0.9218
BSA (m2)	2.222164	0.136
HNV-DNA (LEG/mL)	12.64904	0.0004
HbeAg	9.476967	0.0021

Table 4 Baseline characteristics of patients treated for 2 years¹

	Total (range)	SR-ALT	NR-ALT	SR-DN	NR-DNA
n	147	75	72	85	62
Male/female	112/35	52/23	Dec-60	62/23	Dec-50
ALT (U/L)	221.6±493.5 (17-4491)	258.9±548.5	182.3±428.2	291.3±626.3	122.2±132.0
Albumin (g/dL)	3.8±0.6 (2.2-4.9)	3.8±0.5	3.8±0.6	3.8±0.5	3.9±0.6
Bilirubin (mg/dL)	1.5±2.1 (0.3-12.9)	1.7±2.5	1.3±1.7	1.7±2.6	1.0±1.1
Platelet (104/mL)	13.8±6.2 (3.4-33.6)	12.9±5.4	14.6±6.8	13.1±5.5	14.9±5.6
BSA (m2)	1.71±0.18 (1.30-2.17)	1.67±0.18	1.76±0.17	1.70±0.18	1.73±0.18
HBV-DNA
≤5 (LEG/mL)	18	11	7	12	6
5< ≤6	20	7	13	11	9
6< ≤7	42	23	19	26	16
7<	69	35	34	38	31
HBeAg +/–	82/65	41/34	41/31	41/45	41/20
Age (yr)	48.9±11.4 (19-73)
CH/LC [Child A/B/C]	95/54 [43/3/8]

¹ Data are shown as mean±SD.

Table 5 Univariate analysis of the effects of lamivudine treatment for 2 years

Variables	χ2	P values
Biological effects
ALT (U/L)	0.962196	0.3266
Albumin (g/dL)	0.279331	0.5971
Bilirubin (mg/dL)	1.384215	0.2394
Platelet count (104/mL)	2.943368	0.0862
BSA (m2)	8.339371	0.0039
HNV-DNA (LEG/mL)	0.009964	0.9205
HbeAg	0.077	0.781
Virological effects
ALT (U/L)	8.990505	0.0027
Albumin (g/dL)	0.643271	0.4225
Bilirubin (mg/dL)	3.176521	0.0747
Platelet count (104/mL)	2.064207	0.1508
BSA (m2)	1.060739	0.303
HNV-DNA (LEG/mL)	0.54602	0.4598
HbeAg	5.595	0.018

Table 6 Multivariate analysis of the effects of lamivudine treatment for 2 years

Variables	χ2	P values
Biological effects
Bilirubin (mg/dL)	0.496757	0.4809
Platelet count (104/mL)	0.572997	0.4491
BSA (m2)	2.263849	0.0147
Virological effects
ALT (U/L)	5.482584	0.0192
Bilirubin (mg/dL)	0.983777	0.3212
Platelet count (104/mL)	1.098891	0.2945
BSA (m2)	0.714246	0.398
HNV-DNA (LEG/mL)	0.592857	0.4413
HbeAg	4.101478	0.0428

Table 7 Baseline characteristics of patients treated for 3 years

	Total (range)	SR-ALT	NR-AL	SR-DNA	NR-DNA
n	72	33	39	38	34
Male/female	53/19	21/12	32/7	27/11	26/8
ALT (U/L)	198.6±437.2 (18-3545)	200.0±229.0	197.5±562.1	191.2±218.0	207.2±602.6
Albumin (g/dL)	3.8±0.5 (2.5-4.9)	3.7±0.4	4.0±0.5	3.8±0.5	3.9±0.5
Bilirubin (mg/dL)	1.5±2.1 (0.3-12.9)	1.6±2.2	1.5±2.3	1.6±2.2	1.5±2.4
Platelet (104/mL)	13.8±6.2 (3.9-33.6)	11.6±4.6	15.1±6.9	13.3±5.8	13.8±6.5
BSA (m2)	1.71±0.18 (1.30-2.17)	1.75±0.17	1.66±0.19	1.69±0.17	1.73±0.20
HBV-DNA
≤5 (LEG/mL)	7	4	3	4	3
5< ≤6	15	4	11	6	9
6< ≤7	17	11	6	13	4
7<	33	14	19	15	18
HBeAg +/–	41/31	12/21	20/19	22/16	19/15
Age (yr)	49.5±11.1 (21-73)
CH/LC [Child A/B/C]	43/29 [25/0/4]

¹ Data are shown as mean±SD.

Table 8 Univariate analysis of the effects of lamivudine treatment for 3 years

Variables	χ2	P values
Biological effects
ALT (U/L)	0.000598	0.9805
Albumin (g/dL)	5.541899	0.0186
Bilirubin (mg/dL)	0.100733	0.751
Platelet count (104/mL)	6.242535	0.0125
BSA (m2)	4.393544	0.0361
HNV-DNA (LEG/mL)	0.001477	0.9693
HbeAg	1.113	0.2915
Virological effects
ALT (U/L)	0.023922	0.8771
Albumin (g/dL)	0.565446	0.4315
Bilirubin (mg/dL)	0.010128	0.9198
Platelet count (104/mL)	0.137799	0.7105
BSA (m2)	0.805305	0.3695
HNV-DNA (LEG/mL)	0.065438	0.7981
HBeAg	0.030000	0.8633

Table 9 Multivariate analysis of the effects of lamivudine treatment for 3 years

Variables	χ2	P valuesχ
Biological effects
Albumin (g/dL)	0.865354	0.3522
Platelet count (104/mL)	2.39126	0.122
BSA (m2)	3.213451	0.073
HbeAg	1.252959	0.263